Invasive Breast Cancer Risk

FDA Approves Evista To Reduce Invasive Breast Cancer Risk In Postmenopausal Women With Osteoporosis

Editor's Choice
Main Category: Breast Cancer

Evista (raloxifene HCl), a drug aimed at reducing invasive breast cancer risk for both postmenopausal women with osteoporosis and postmenopausal women with a invasive breast cancer risk has been approved by the US Food and Drug Administration (FDA) for both groups of women ...

FDA Approves Evista To Reduce Invasive Breast Cancer Risk In Postmenopausal Women With Osteoporosis

breast cancer research

Cancer Survival Stories
Shared, first-hand breast cancer survivor stories through their eyes
CancerCenter.com/CareThatNeverQuits

Radiation Treatment
Seed and External Beam in Atlanta. Cure rate data on over 14,000 men.
ProstRcision.com

New Cancer Treatment
4x Better Survival Rates Than Chemo or Radiotherapy
CancerTreatmentMX.com

Helping Fight Breast Cancer
Marshall receives grant for breast cancer research

Marshall University is getting a $266,000 federal grant to study possible links between diet and breast cancer. 2007

Congressman Nick Rahall says researchers want to identify
dietary changes that could reduce the risk of breast cancer. In
particular, they will look at omega-3 fatty acids that are found in
fish in nuts.

Studies have shown patients with heart disease benefit from
eating omega-3 fatty acids.

Marshall's Joan C. Edwards School of Medicine received the grant
from the U.S. Department of Health and Human Services' National
Cancer Institute.